Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer

Read also

Eli Lilly

Eli Lilly picks Virginia for $5bn drug manufacturing plant

Modus

Modus data on sevuparin for CKD to be presented at global GAG symposium

Biocon Biologics

Biocon Biologics Says FDA Approves Bosaya And Aukelso As Denosumab Biosimilars

Nurix reports

Nurix reports promising preclinical data for IRAK4 degrader GS-6791